SVCM
ELVN icon

Saturn V Capital Management’s Enliven Therapeutics ELVN Stock Holding History

Saturn V Capital Management’s Portfolio ELVN Stock Details ELVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-152,178
Closed -$3.56M – 27
2024
Q2 		$3.56M Buy
+152,178
New +$3.2M 1.34% 22

Other funds holding ELVN

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Saturn V Capital Management's ELVN Position: Q3 2024 in Review

Saturn V Capital Management sold out of Enliven Therapeutics (ELVN) in Q3 2024, closing a stake of 152,178 shares — an estimated $3.56M sold.

Saturn V Capital Management first reported a position in ELVN in Q2 2024 and held it in 1 quarter. The position peaked at $3.56M in Q2 2024. 102 funds tracked by Wall St. Rank hold ELVN as of Q3 2024.

  • Saturn V Capital Management reported no remaining Enliven Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Saturn V Capital Management sold 152,178 Enliven Therapeutics shares in Q3 2024, an estimated $3.56M.
  • Saturn V Capital Management first reported a position in Enliven Therapeutics in Q2 2024 and held it in 1 quarter.
  • Saturn V Capital Management's Enliven Therapeutics position peaked at $3.56M in Q2 2024.
  • 102 funds tracked by Wall St. Rank held Enliven Therapeutics as of Q3 2024.

Based on Saturn V Capital Management's 13F filing for Q3 2024, filed 14 Nov 2024.